Novartis (NVS) Tops Q1 EPS by 13c, raises guidance

Novartis (NYSE: NVS) reported Q1 EPS of $1.80, $0.13 better than the analyst estimate of $1.67. Revenue for the quarter came in at $11.83 billion versus the consensus estimate of $11.43 billion.

Net sales are expected to grow high single to low double-digit (from mid-single-digit).
Core operating income is expected to grow low double-digit to mid-teens (from high single-digit).

For earnings history and earnings-related data on Novartis (NVS) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• H.B. Fuller (FUL) Tops Q3 EPS by 5c, Misses on Revenue; Offers FY26 EPS Guidance
• B. Riley’s Top Biotech Picks Ahead of 3Q26 Earnings Season